AICAR

Mechanism

AICAR is often called the "exercise in a bottle" peptide because it activates the same energy-sensing pathway (AMPK) that is triggered by physical exercise. When AMPK is activated, cells increase fat burning, glucose uptake, and mitochondrial production — the same metabolic benefits you get from working out. It has been studied for endurance enhancement, fat loss, and protection against muscle wasting, though its effects are broad since AMPK influences nearly every metabolic pathway in the body.

Effects

METABOLIC: Primary target system. Activates AMPK — the master metabolic energy sensor that responds to low ATP/AMP ratios. AMPK activation triggers: increased GLUT4 translocation and glucose uptake in skeletal muscle (mimics exercise-induced glucose clearance); enhanced fatty acid oxidation via phosphorylation of acetyl-CoA carboxylase (ACC) and derepression of CPT-1; stimulation of mitochondrial biogenesis via PGC-1alpha activation; suppression of mTOR-mediated anabolic processes and lipogenesis. In DIO mouse models: reduced body weight, improved insulin sensitivity, enhanced endurance capacity. MUSCULOSKELETAL: Key application. Prevents inflammation-associated cachexia (muscle wasting) in multiple mouse models — IFNγ/TNFα-induced atrophy was suppressed by AICAR but NOT by metformin (EMBO Molecular Medicine, 2018, PMID: 29844217). This distinguishes AICAR from metformin despite both activating AMPK (suggesting AMPK-independent anti-cachectic mechanisms). Enhances endurance capacity in sedentary mice by 44% (Narkar et al., 2008 — the famous 'exercise in a bottle' paper). Increases slow-twitch (Type I) muscle fiber proportion. CARDIOVASCULAR: Studied as cardioprotective agent during cardiac surgery — reduces myocardial ischemia-reperfusion injury. Entered Phase III clinical trials for cardiac ischemia (acadesine, Schering-Plough) but was discontinued due to mixed results. Adenosine receptor agonism provides vasodilation. IMMUNE: Suppresses NF-kB-mediated inflammatory signaling (partially AMPK-independent). Anti-inflammatory effects in multiple cell types. Reduces pro-inflammatory cytokine production. NEUROLOGICAL: AMPK activation in neurons promotes autophagy and clearance of damaged mitochondria (mitophagy), potentially neuroprotective. However, excessive AMPK activation in neurons can be detrimental — context-dependent effects. ENDOCRINE: Improves insulin sensitivity — directly relevant to metabolic syndrome and prediabetes. Reduces hepatic glucose output. HEPATIC: Suppresses hepatic lipogenesis via AMPK-ACC axis. Reduces liver fat accumulation in animal models. IMPORTANT NOTE: Many AICAR effects previously attributed to AMPK activation are AMPK-independent (systematic review: Cells, 2021, PMID: 34066424). Adenosine receptor agonism, direct effects on purine metabolism, and other off-target mechanisms contribute significantly. Tier 3: Used in athletic performance community as an endurance enhancer. Banned by WADA. Practitioner use is limited due to cost, injection requirement, and lack of human dosing data.

Practitioner Guide

DOSING TIPS: No established human dosing protocol. Animal studies typically used 500 mg/kg/day subcutaneous (very high dose, not directly translatable). Practitioner protocols (limited): 25-50 mg subcutaneous injection daily for 4-6 weeks. Some practitioners use 50-150 mg daily. This is highly experimental — start at the lowest dose. Oral bioavailability is poor — injectable is the standard route. RECONSTITUTION: Lyophilized powder — reconstitute with bacteriostatic water. For a 50mg vial: add 1mL BAC water = 50mg/mL. Use insulin syringe for SubQ injection. Solutions may be slightly acidic — some users report mild stinging at injection site. INJECTION SITE: Subcutaneous — abdominal fat pad (rotate sites). Can be injected IM but no advantage over SubQ for this compound. TIMING: Before exercise for maximum endurance benefit (30-60 minutes pre-workout). For general metabolic effects, morning injection. SUPPLEMENT SYNERGIES: Pairs with GW501516 (PPAR-delta agonist) — the combination enhanced endurance more than either alone in the original Narkar et al. study. However, GW501516 has carcinogenicity concerns in animal models. Stack with L-carnitine for enhanced fatty acid transport. Combine with CoQ10 for mitochondrial support. Berberine or metformin may have additive AMPK effects, but redundancy reduces utility. CYCLING: Recommended — 4-6 weeks on, 4 weeks off. No data on long-term continuous use in humans. AMPK activation should likely be cyclical to avoid chronic mTOR suppression (which could impair muscle protein synthesis). STACKING: Endurance stack: AICAR + BPC-157 (joint support) + electrolytes. Fat loss: AICAR + 5-Amino-1MQ + MOTS-c (three different metabolic pathways). Longevity: AICAR + Epithalon + NAD+ precursor. CONTRAINDICATION NUANCES: Not a peptide — it is a nucleoside analog. AMPK activation may suppress mTOR — potentially antagonistic to muscle-building goals (avoid stacking with anabolics intended for hypertrophy). Diabetic patients on insulin or sulfonylureas — additive hypoglycemia risk. Patients with cardiac arrhythmias — adenosine effects may worsen. Banned by WADA — athletes subject to testing should avoid. STORAGE: Lyophilized — room temperature or refrigerated, protect from light and moisture. Reconstituted — refrigerate, use within 4-6 weeks. PATIENT EDUCATION: This is the original "exercise mimetic" — the 2008 paper showing sedentary mice running 44% longer made global headlines. However, it is NOT a replacement for exercise — exercise activates hundreds of pathways; AICAR activates mainly AMPK. Think of it as amplifying one particular exercise benefit (endurance/fat oxidation). Banned by WADA since 2009. No approved human dose exists. Side effects in animals include hypoglycemia at high doses. This is among the most experimental compounds in the peptide world.

Evidence

• Chronic treatment of old mice with AICAR reverses age-related changes in exercise performance and skeletal muscle gene expression.

  Wilcox SH, et al. (2025) — FASEB BioAdvances — PMID: 40060947

  In 23-month-old mice treated daily for 31 days, AICAR prevented the decline in treadmill performance, increased quadriceps mass by roughly 8%, improved EDL tetanic force by about 26%, and shifted mitochondrial and Akt-related gene-expression markers toward a more youthful profile. The paper supports AMPK-activation plausibility for sarcopenia and performance maintenance, but remains animal-only evidence.

  emerging

Research Summary

TIER 1 (Gold Standard): Narkar et al., 2008 — AMPK and PPARδ agonists are exercise mimetics (Cell, PMID: 18674809). This landmark paper showed AICAR increased endurance by 44% in sedentary mice. Hall et al., 2018 — AICAR prevents inflammation-associated cachectic muscle wasting (EMBO Molecular Medicine, PMID: 29844217). Acadesine cardiac ischemia Phase III trials (mixed results, discontinued). Multiple RCTs of AMPK activation in metabolic disease (though typically using metformin as the AMPK activator). TIER 2 (Strong): Merrill et al., 1997 — AICAR activates AMPK in skeletal muscle. Winder et al., 2000 — AMPK activation effects on fatty acid oxidation. Systematic review: AICAr has important AMPK-independent effects (Cells, 2021, PMID: 34066424). WADA prohibited list documentation. TIER 3 (Moderate): Athletic performance community use documented in sports medicine literature and anti-doping cases. Limited practitioner case series for metabolic optimization. Community reports on endurance enhancement. Cost and injection requirements limit clinical adoption. KEY FINDINGS: (1) AICAR is a genuine exercise mimetic for endurance and fat oxidation. (2) Anti-cachectic effects are unique and not shared by metformin. (3) Many effects are AMPK-independent — the compound is more complex than originally understood. (4) Phase III cardiac trials failed — limiting pharmaceutical development interest. (5) No established human dosing protocol. GAPS: Optimal human dosing. Long-term safety. Tissue-specific effects. AMPK-dependent vs. independent effect profiles in humans. Combination effects with exercise. ACTIVE TRIALS: No active trials for AICAR as a metabolic modulator on ClinicalTrials.gov.